Answers are grounded in this paper and cite their sources.
Examines drug delivery enhancements in oral carcinoma using SLNs and antibody conjugation, indicating significant therapeutic potential.
This preliminary study explores a dual strategy of augmenting anticancer therapy with Carboplatin-loaded solid lipid nanoparticles (SLNs) alongside antigen-specific antibodies through immunization of KB oral carcinoma cells. KB and Sp2/01 myeloma cells were cultured and assessed for viability. Female Balb/c mice were immunized with KB cells, resulting in significant weight gainand spleen enlargement, suggesting immune activation. Enzyme-linked immunosorbent assay (ELISA) confirmed the production of antigen-specific antibodies, as indicated by an increase in absorbance at a 1:1000 serum dilution. Splenocytes from immunized mice were fused with myeloma cells using polyethylene glycol (PEG), with optimal hybridoma generation achieved in the third trial. SLNs were formulated by the microemulsion method, which exhibited favourable physicochemical properties (particle size: 144.57 nm, PDI: 0.261, zeta potential: -32 mV). Cytotoxicity assays revealed time- and dose-dependent cytotoxic effects against oral squamous cell carcinoma (OSCC), with SLNs demonstrating greater potency compared to free Carboplatin. These findings underscore the promise of SLNs in cancer therapy and the generation of KB cell-targeting antibodies using hybridoma technology.
No takes yet. Share an insight, caveat, or question.
Patil et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: